NASDAQ$VYGR
Voyager Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Voyager Therapeutics reported financial results for Q1 2022 and provided a business update.
Voyager Therapeutics reported a net loss of $21.3 million for the first quarter of 2022, with collaboration revenue of $0.7 million. The company's cash, cash equivalents, and marketable debt securities totaled $166.8 million as of March 31, 2022, expected to fund operations into 2024. Voyager continued to advance its TRACER capsid discovery platform and pipeline programs, including a license option agreement with Novartis.
- Executed license option agreement with Novartis for target-specific access to next-generation TRACER AAV capsids
- Alfred W. Sandrock, Jr., M.D., Ph.D. appointed as Chief Executive Officer and Board Member
- Cash runway into 2024
- Voyager to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
Headline financials
Revenue & EPS history
Voyager Therapeutics · Revenue · Quarterly
$658K
Revenue by segment
Voyager Therapeutics · $700K total across 1 segment · Q1 2022
- Collaboration Revenue$700K—100.0%
Forward guidance
Voyager expects that its cash, cash equivalents, and marketable debt securities will be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+0.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+2.3%
Avg return
30 days after
45%
19 / 42 earnings
Positive
+60.3%
Q4 2021
Best reaction
-21.7%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.0% | -0.5% | — | |
| Q4 2025 | +21.7% | +8.5% | -3.6% | |
| Q3 2025 | +0.0% | -7.7% | +3.5% | |
| Q1 2025 | +0.0% | -9.4% | +0.3% | |
| Q4 2024 | +2.3% | -2.0% | -20.2% | |
| Q3 2024 | -4.6% | -19.5% | -10.8% | |
| Q2 2024 | -11.7% | -13.2% | -20.5% | |
| Q1 2024 | -1.5% | -1.1% | -1.8% | |
| Q4 2023 | -6.6% | +8.2% | +4.5% | |
| Q3 2023 | +1.6% | -5.4% | +13.4% | |
| Q2 2023 | -1.7% | -1.2% | +12.2% | |
| Q1 2023 | +19.0% | +25.6% | +53.9% | |
| Q4 2022 | +2.1% | -5.5% | +0.4% | |
| Q3 2022 | +6.5% | +14.6% | +25.7% | |
| Q2 2022 | -2.0% | -13.6% | -6.4% | |
| Q1 2022 | -18.4% | -38.0% | -23.9% | |
| Q4 2021 | +60.3% | +42.2% | +129.8% | |
| Q3 2021 | +7.5% | +2.4% | -21.0% | |
| Q2 2021 | +10.4% | -3.1% | +4.7% | |
| Q1 2021 | +2.1% | +5.6% | +9.1% | |
| Q4 2020 | -14.0% | -14.0% | -26.9% | |
| Q3 2020 | -21.7% | -22.1% | -28.1% | |
| Q2 2020 | +0.1% | +0.7% | -6.8% | |
| Q1 2020 | -5.9% | +8.0% | +4.9% | |
| Q4 2019 | +6.6% | -3.3% | -23.3% | |
| Q3 2019 | -2.6% | -5.0% | -5.9% | |
| Q2 2019 | -2.8% | +2.3% | -21.1% | |
| Q1 2019 | +1.9% | +1.6% | -4.3% | |
| Q4 2018 | +11.5% | +19.0% | +37.0% | |
| Q3 2018 | -9.6% | -15.6% | -21.3% | |
| Q2 2018 | -15.7% | -10.5% | -3.6% | |
| Q1 2018 | -4.3% | +8.0% | +17.6% | |
| Q4 2017 | -9.9% | -13.2% | -22.7% | |
| Q3 2017 | -17.5% | -34.6% | -29.5% | |
| Q2 2017 | +6.6% | +4.3% | +71.7% | |
| Q1 2017 | +6.1% | +4.0% | -0.1% | |
| Q4 2016 | -1.9% | -0.3% | -2.5% | |
| Q3 2016 | +2.9% | +17.3% | +21.4% | |
| Q2 2016 | +3.0% | +2.8% | -18.3% | |
| Q1 2016 | -6.5% | — | — | |
| Q4 2015 | -7.2% | — | — | |
| Q3 2015 | +9.2% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro